-+ 0.00%
-+ 0.00%
-+ 0.00%

VistaGen says FDA clears Phase 2 refisolone study for menopausal hot flashes

PUBT·04/22/2026 12:32:22
Listen to the news
VistaGen says FDA clears Phase 2 refisolone study for menopausal hot flashes
  • VistaGen received an FDA “Study May Proceed” letter under its IND for refisolone nasal spray, clearing further Phase 2 development in US for menopausal hot flashes.
  • Phase 2a data cited hot flash frequency fell 80% with refisolone versus 36% with placebo in a 36-patient study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604220830BIZWIRE_USPR_____20260422_BW186960) on April 22, 2026, and is solely responsible for the information contained therein.